A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

Blood

Volumn 118, Issue 24, 2011, Pages 6299-6305

  Cuker, Adam ^a   Coles, Alasdair J ^b   Sullivan, Herman ^c   Fox, Edward ^d   Goldberg, Mark ^e   Oyuela, Pedro ^e   Purvis, Annie ^e   Beardsley, Diana S ^f   Margolin, David H ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Hauenstein Neuroscience Center   (United States)

^d Multiple Sclerosis Clinic of Central Texas   (United States)

^e GENZYME CORPORATION   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; IMMUNOGLOBULIN G; METHYLPREDNISOLONE SODIUM SUCCINATE; RHESUS D ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BRAIN HEMORRHAGE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; FEMALE; FETAL HEMORRHAGE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 83455210452     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-371138     Document Type: Article

References (37)

1. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
2. Rodegheiro F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11): 2386-2393.
3. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413.
4. Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2010;2010(4):377-384.
5. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
6. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009;145(2):235-244.
7. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombcytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83-89.
8. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377-2383. (Pubitemid 44575432)
9. Sahraian MA, Eshaghi A. Concomitant multiple sclerosis and idiopathic thrombocytopenic purpura. Eur J Neurol. 2010;17(8):e62-e63.
10. Granier H, Bellard S, Nicolas X, Laborde JP, Talarmin F. Association of multiple sclerosis and autoimmune thrombocytopenia. Rev Med Interne. 2001;22(12):1271-1272. (Pubitemid 34007795)
11. Rebif prescribing information. http://media.pfizer.com/files/products/ uspi-rebif.pdf. Revised September 2009. Accessed April 25, 2011.
12. Copaxone prescribing information. http://www. sharedsolutions.com/pdfs/ PrescribingInformation. aspx. Revised February 2009. Accessed June 13, 2011.
13. Betaseron prescribing information. http://berlex. bayerhealthcare.com/ html/products/pi/Betaseron-PI.pdf. Revised May 2010. Accessed June 13, 2011.
14. Avonex prescribing information. http://www. avonex.com/pdfs/pi-luer-lock. pdf. Issued June 2011. Accessed May 31, 2011.
15. Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011;77(5):505-507.
16. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998; 129(11):886-890. (Pubitemid 28549817)
17. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol. 1997;52(3):183-189. (Pubitemid 27278372)
18. Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol. 2002;81(8):436-440. (Pubitemid 36067657)
19. Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94(2):178-184. (Pubitemid 40343692)
20. Otton SH, Turner DL, Frewin R, Davies SV, Johnson SA. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukemia [letter]. Br J Haematol. 1999;106(1):261-262. (Pubitemid 29343567)
21. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology. 2004;9(5-6):409-411. (Pubitemid 40123592)
22. Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant patients. Haematologica. 2007;92(8): 1029-1036. (Pubitemid 350144208)
23. Treon SP, Soumerai JD, Hunter ZR, et al. Longterm follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011;118(2):276-281.
24. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783-4785.
25. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with CAMPATH-1H in patients with autoimmune cytopenias. Br J Haematol. 2001; 114(4):891-898. (Pubitemid 32953751)
26. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2009;4(1):47-53.
27. Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine. 2005;84(2):98-106. (Pubitemid 40418638)
28. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves'disease after immune restoration in severely immunocompromised human immunodeficiency virus-1 infected patients. J Clin Endocrinol Metab. 2000;85(11):4254-4257. (Pubitemid 32055382)
29. Hequet O, Salles G, Ketterer N, et al. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant. 2003;32(1):89-95. (Pubitemid 36850285)
30. Jillella AP, Kallab AM, Kutlar A. Autoimmune thrombocytopenia following autologous hematopoietic stem cell transplantation: review of literature and treatment options. Bone Marrow Transplant. 2000;26(8):925-927.
31. Heelan BT, Tormey V, Amlot P, Payne E, Mehta A, Webster AD. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol. 2002; 118(4):1078-1081. (Pubitemid 35025972)
32. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114(15):3167-3172.
33. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009; 119(7):2052-2061.
34. Semple JW, Provan D, Garvey MB, Freedman J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol. 2010;17(6):590-595.
35. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579.
36. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163-1175.
37. Berchtold P, Muller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol. 1997;96(3):477-483. (Pubitemid 27087230)